( The Hill ) — The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain among patients with knee osteoarthritis and obesity.
The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ingredient semaglutide or a placebo for 68 weeks. Roughly 82 percent of participants were women.
Even the skeptics agree: Kern County Museum appears to have a ghostly presence or two
To measure pain, researchers used the Western Ontario and McMaster Universities Arthritis Index (WOMAC). The WOMAC involves participants scoring pain, difficulty and physical function when doing everyday activities like walking up and down stairs or sitting.
At the start of the trial, the average WOMAC pain score among participants was 70.9. By the 68th week, those taking semaglutide reported an average WOMAC pain score of 29.2 while those taking a placebo reported an average pain score of 43.4.
Never miss a story: Make KGET.com your homepage
The semaglutide participants on average had a body weight reduction of 13.7 percent while those taking a placebo had a 3.2 percent reduction on average…